Eva Kasanda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eva Kasanda has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Vinzenz Bildstein
University of Guelph
6 shared publications - Dennis Mücher
Universität zu Köln
5 shared publications - Alexander Gottstein
Albert Einstein Center for Fundamental Physics (AEC), Laboratory for High Energy Physics (LHEP), University of Bern, Sidlerstrasse 5, CH-3012 Bern, Switzerland
4 shared publications C Höhr
TRIUMF, 4004 Wesbrook Mall, Vancouver, British Columbia, V6T 2A3, Canada
4 shared publications- Lars Eggimann
Albert Einstein Center for Fundamental Physics (AEC), Laboratory for High Energy Physics (LHEP), University of Bern, Sidlerstrasse 5, CH-3012 Bern, Switzerland
4 shared publications - Saverio Braccini
Albert Einstein Center for Fundamental Physics (AEC), Laboratory for High Energy Physics (LHEP), University of Bern, Sidlerstrasse 5, CH-3012 Bern, Switzerland
4 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by IOP Publishing in Journal of Instrumentation
- Vol. 21 (08) , P08030
Development of a proton therapy research beamline with FLASH and minibeam capabilities at the 18 MeV Bern Medical Cyclotron
Advanced radiotherapy approaches such as FLASH irradiation and spatially fractionated radiotherapy (SFRT) show potential to improve the therapeutic ratio, yet their biological mechanisms and optimal delivery parameters remain uncertain. Progress requires accessible proton research platforms with flexible temporal and spatial dose delivery. We report on the adaptation of the Beam Transfer Line (BTL) of the Bern Medical Cyclotron (BMC) for radiobiology research with FLASH and proton minibeam capabilities. The BMC is optimized for the production of radionuclides for medical imaging, and is able to extract currents up to 150 μA. The 18 MeV proton beam was passively shaped using collimators, scattering foils, and extended drift space to generate irradiation fields. A dosimetric framework was implemented using an in-beam ionization chamber and radiochromic film with LET-dependent corrections. Beam uniformity and SFRT profiles with various grid spacings were evaluated at realistic target distances. The developed beamline enables stable delivery under controlled conditions in both conventional and FLASH regimes, spanning dose rates from 0.01 to 100 Gy s -1 . Dose uniformity within a 20 mm radius was below 8%. Film measurements confirmed the need for LET-dependent corrections and indicated that quantitative dosimetry in in-vitro setups is achievable with appropriate LET corrections. The low proton energy (15.54(12) MeV extracted into air, 8.14(28) MeV delivered to cells in flask) facilitates compact SFRT implementation with well-resolved minibeams. The adapted BMC provides a flexible and accessible platform for systematic pre-clinical proton radiobiology studies under varied dose-rate and spatial delivery conditions. This supports optimization of emerging modalities such as proton FLASH and SFRT and helps bridge accelerator technology and radiobiology.
- 1 August 2026
- Published by IOP Publishing in Journal of Instrumentation
- Vol. 21 (08) , P08030
Open AccessDevelopment of a proton therapy research beamline with FLASH and minibeam capabilities at the 18 MeV Bern Medical Cyclotron
Advanced radiotherapy approaches such as FLASH irradiation and spatially fractionated radiotherapy (SFRT) show potential to improve the therapeutic ratio, yet their biological mechanisms and optimal delivery parameters remain uncertain. Progress requires accessible proton research platforms with flexible temporal and spatial dose delivery. We report on the adaptation of the Beam Transfer Line (BTL) of the Bern Medical Cyclotron (BMC) for radiobiology research with FLASH and proton minibeam capabilities. The BMC is optimized for the production of radionuclides for medical imaging, and is able to extract currents up to 150 μA. The 18 MeV proton beam was passively shaped using collimators, scattering foils, and extended drift space to generate irradiation fields. A dosimetric framework was implemented using an in-beam ionization chamber and radiochromic film with LET-dependent corrections. Beam uniformity and SFRT profiles with various grid spacings were evaluated at realistic target distances. The developed beamline enables stable delivery under controlled conditions in both conventional and FLASH regimes, spanning dose rates from 0.01 to 100 Gy s -1 . Dose uniformity within a 20 mm radius was below 8%. Film measurements confirmed the need for LET-dependent corrections and indicated that quantitative dosimetry in in-vitro setups is achievable with appropriate LET corrections. The low proton energy (15.54(12) MeV extracted into air, 8.14(28) MeV delivered to cells in flask) facilitates compact SFRT implementation with well-resolved minibeams. The adapted BMC provides a flexible and accessible platform for systematic pre-clinical proton radiobiology studies under varied dose-rate and spatial delivery conditions. This supports optimization of emerging modalities such as proton FLASH and SFRT and helps bridge accelerator technology and radiobiology.
- 17 June 2026
- Published by American Physical Society (APS) in Physical Review C
- Vol. 113 (6)
Measurement of high-energy resonances in Ne 22 through inverse kinematics
- 17 June 2026
- Published by American Physical Society (APS) in Physical Review C
- Vol. 113 (6)
Measurement of high-energy resonances in Ne 22 through inverse kinematics
- Open Access
- 1 June 2026
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 236, 112727
Cross-section measurements of lanthanum radioisotopes towards an optimized production of 133La and 135La for theranostic applications
- 1 June 2026
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 236, 112727
Open AccessCross-section measurements of lanthanum radioisotopes towards an optimized production of 133La and 135La for theranostic applications
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Cross-section measurements of lanthanum radioisotopes towards an optimized production of 133La and 135La for theranostic applications
The theranostic pair 133La/135La has recently attracted growing interest as a promising candidate for combined diagnostic and therapeutic applications, owing to the favorable nuclear and chemical properties of lanthanum. 135La (t1/2 = 18.91 h) decays by electron capture (EC) to the ground state of 135Ba, emitting Auger cascade electrons that are potentially useful for targeted internal radiotherapy. In contrast, 133La (t1/2 = 3.912 h) is a β+-emitter suitable for PET imaging. Moreover, 133La has been proposed as a diagnostic partner for 225Ac (t1/2 = 9.9 d), due to their close chemical similarity and the longer half-life of 133La compared with other PET radiometals such as 68Ga (t1/2 = 1.13 h).A feasible approach for producing 133La and 135La is the irradiation of enriched 134Ba and 135Ba targets, respectively, with low- to medium-energy proton beams (up to 25 MeV maximal energy) readily available from medical cyclotrons. Although these production routes have been previously explored, the available nuclear data on lanthanum radioisotopes remain limited and often inconsistent. In this work, we measured the cross sections of reactions producing lanthanum isotopes up to 18 MeV, using natural BaCO3 as well as enriched 134BaCO3 and 135BaCO3 targets, with some cross sections reported here for the first time. The half-lives of La radioisotopes were also determined and compared with the literature values. The resulting data were used to optimize the production parameters for 1La and 135La, and several irradiation tests were carried out to validate our findings.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCross-section measurements of lanthanum radioisotopes towards an optimized production of 133La and 135La for theranostic applications
The theranostic pair 133La/135La has recently attracted growing interest as a promising candidate for combined diagnostic and therapeutic applications, owing to the favorable nuclear and chemical properties of lanthanum. 135La (t1/2 = 18.91 h) decays by electron capture (EC) to the ground state of 135Ba, emitting Auger cascade electrons that are potentially useful for targeted internal radiotherapy. In contrast, 133La (t1/2 = 3.912 h) is a β+-emitter suitable for PET imaging. Moreover, 133La has been proposed as a diagnostic partner for 225Ac (t1/2 = 9.9 d), due to their close chemical similarity and the longer half-life of 133La compared with other PET radiometals such as 68Ga (t1/2 = 1.13 h).A feasible approach for producing 133La and 135La is the irradiation of enriched 134Ba and 135Ba targets, respectively, with low- to medium-energy proton beams (up to 25 MeV maximal energy) readily available from medical cyclotrons. Although these production routes have been previously explored, the available nuclear data on lanthanum radioisotopes remain limited and often inconsistent. In this work, we measured the cross sections of reactions producing lanthanum isotopes up to 18 MeV, using natural BaCO3 as well as enriched 134BaCO3 and 135BaCO3 targets, with some cross sections reported here for the first time. The half-lives of La radioisotopes were also determined and compared with the literature values. The resulting data were used to optimize the production parameters for 1La and 135La, and several irradiation tests were carried out to validate our findings.
- Open Access
- 1 March 2026
- Published by IOP Publishing in Journal of Instrumentation
- Vol. 21 (03) , P03036
Non-destructive beam monitoring via secondary radiation detection with Ce-doped silica fibers
Non-destructive beam diagnostics are essential for low-energy medical cyclotrons, where even thin interceptive devices can severely degrade beam quality. We investigate an external fiber monitor (EFM) based on Ce-doped silica scintillating fibers that detects secondary radiation generated at existing beamline components of the 18 MeV Bern Medical Cyclotron beam transfer line (BTL). Three use cases were studied: (i) beam intensity monitoring around an electrically isolated, water-cooled beam dump; (ii) beam-loss monitoring around a 10 mm collimator under varying the beam focusing; and (iii) by steering a 6×6 mm beam spot on a beam dump. For case (i), the summed EFM signal exhibits a linear dependence on the current on target over nearly three orders of magnitude. In case (ii), a normalized EFM-based beam-loss proxy scales monotonically with an electrical loss proxy across several focusing settings. Furthermore, opposing-fiber signal ratios provide decoupled, monotonic sensitivity to horizontal and vertical beam displacements.
- 1 March 2026
- Published by IOP Publishing in Journal of Instrumentation
- Vol. 21 (03) , P03036
Open AccessNon-destructive beam monitoring via secondary radiation detection with Ce-doped silica fibers
Non-destructive beam diagnostics are essential for low-energy medical cyclotrons, where even thin interceptive devices can severely degrade beam quality. We investigate an external fiber monitor (EFM) based on Ce-doped silica scintillating fibers that detects secondary radiation generated at existing beamline components of the 18 MeV Bern Medical Cyclotron beam transfer line (BTL). Three use cases were studied: (i) beam intensity monitoring around an electrically isolated, water-cooled beam dump; (ii) beam-loss monitoring around a 10 mm collimator under varying the beam focusing; and (iii) by steering a 6×6 mm beam spot on a beam dump. For case (i), the summed EFM signal exhibits a linear dependence on the current on target over nearly three orders of magnitude. In case (ii), a normalized EFM-based beam-loss proxy scales monotonically with an electrical loss proxy across several focusing settings. Furthermore, opposing-fiber signal ratios provide decoupled, monotonic sensitivity to horizontal and vertical beam displacements.
- Open Access
- 19 December 2025
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 1084
Beam energy measurement using a Bayesian approach with the stacked foil method
- 19 December 2025
- Published by Elsevier in Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
- Vol. 1084
Open AccessBeam energy measurement using a Bayesian approach with the stacked foil method
- Open Access
- 5 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 23 (22) , 27343-27350
Radiation Response of Perfluorinated Polymer Optical Fibers (CYTOP) to Low Doses of X-Rays, Protons, and Neutrons
The response of perfluorinated polymer fibres (PF-POF) in X-ray, proton and neutron irradiation was investigated for their potential application in clinical environments. Radiation-induced attenuation in PF-POF increases linearly with dose and PF-POF was found to be highly sensitive to all the sources of radiation used. A sensitivity of 0.050 ± 0.003, 0.089 ± 0.005 and 0.065 ± 0.003 dB/m/Gy was recorded for 6 MV X rays, 63 MeV protons and 400 MeV neutrons, respectively, at a wavelength of 510 nm at room temperature. The PF-POF fibres also exhibit energy dependence - a useful feature in characterizing the depth dose in a proton beam. The high sensitivity of the fibre enables the development of distributed sensing in oncology and can be combined with other solid-state detectors in monitoring radiation dose in mixed radiation environments.
- 5 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 23 (22) , 27343-27350
Open AccessRadiation Response of Perfluorinated Polymer Optical Fibers (CYTOP) to Low Doses of X-Rays, Protons, and Neutrons
The response of perfluorinated polymer fibres (PF-POF) in X-ray, proton and neutron irradiation was investigated for their potential application in clinical environments. Radiation-induced attenuation in PF-POF increases linearly with dose and PF-POF was found to be highly sensitive to all the sources of radiation used. A sensitivity of 0.050 ± 0.003, 0.089 ± 0.005 and 0.065 ± 0.003 dB/m/Gy was recorded for 6 MV X rays, 63 MeV protons and 400 MeV neutrons, respectively, at a wavelength of 510 nm at room temperature. The PF-POF fibres also exhibit energy dependence - a useful feature in characterizing the depth dose in a proton beam. The high sensitivity of the fibre enables the development of distributed sensing in oncology and can be combined with other solid-state detectors in monitoring radiation dose in mixed radiation environments.
- Open Access
- 25 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (19) , 195018
Range verification in heavy-ion therapy using a hadron tumour marker
Objective. A new method to estimate the range of an ion beam in a patient during heavy-ion therapy was investigated, which was previously verified for application in proton therapy. Approach. The method consists of placing a hadron tumour marker (HTM) close to the tumour. As the treatment beam impinges on the HTM, the marker undergoes nuclear reactions. When the HTM material is carefully chosen, the activation results in the emission of several delayed, characteristic γ rays, whose intensities are correlated with the remaining range inside the patient. When not just one but two reaction channels are investigated, the ratio between these two γ ray emissions can be measured, and the ratio is independent of any beam delivery uncertainties. Main results. A proof-of-principle experiment with an 16O ion beam and Ag foils as HTM was successfully executed. The 107Ag(16O, x)112Sb and the 107Ag(16O, x)114Sb reaction channels were identified as suitable for the HTM technique. When only one γ-ray emission is measured, the resulting range-uncertainty estimation is at the 0.5 mm scale. When both channels are considered, a theoretical limit on the range uncertainty of a clinical fiducal marker was found to be ±290 μm. Significance. Range uncertainty of a heavy-ion beam limits the prescribed treatment plan for cancer patients, especially the direction of the ion beam in relation to any organ at risk. An easy to implement range-verification technique which can be utilized during clinical treatment would allow treatment plans to take full advantage of the sharp fall-off of the Bragg peak without the risk of depositing excessive dose into healthy tissue.
- 25 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (19) , 195018
Open AccessRange verification in heavy-ion therapy using a hadron tumour marker
Objective. A new method to estimate the range of an ion beam in a patient during heavy-ion therapy was investigated, which was previously verified for application in proton therapy. Approach. The method consists of placing a hadron tumour marker (HTM) close to the tumour. As the treatment beam impinges on the HTM, the marker undergoes nuclear reactions. When the HTM material is carefully chosen, the activation results in the emission of several delayed, characteristic γ rays, whose intensities are correlated with the remaining range inside the patient. When not just one but two reaction channels are investigated, the ratio between these two γ ray emissions can be measured, and the ratio is independent of any beam delivery uncertainties. Main results. A proof-of-principle experiment with an 16O ion beam and Ag foils as HTM was successfully executed. The 107Ag(16O, x)112Sb and the 107Ag(16O, x)114Sb reaction channels were identified as suitable for the HTM technique. When only one γ-ray emission is measured, the resulting range-uncertainty estimation is at the 0.5 mm scale. When both channels are considered, a theoretical limit on the range uncertainty of a clinical fiducal marker was found to be ±290 μm. Significance. Range uncertainty of a heavy-ion beam limits the prescribed treatment plan for cancer patients, especially the direction of the ion beam in relation to any organ at risk. An easy to implement range-verification technique which can be utilized during clinical treatment would allow treatment plans to take full advantage of the sharp fall-off of the Bragg peak without the risk of depositing excessive dose into healthy tissue.
- Open Access
- 8 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (18) , 185005
Improved sub-milimeter range-verification method for proton therapy using a composite hadron tumour marker (HTM)
Objective. The results of a follow-up experiment investigating a novel method for sub-milimetre range verification (RV) in proton therapy (PT) are presented. Approach. The method consists of implanting a hadron tumour marker (HTM) near the planned treatment volume, and measuring the γ-ray signals emitted as a result of activation by the proton beam. These signals are highly correlated with the energy of the beam impinging on the HTM and can provide an absolute measurement of the range of the beam relative to the position of the HTM, which is independent of any uncertainties in beam delivery. Main results. Three candidate HTM materials were identified and combined into a single composite HTM, which makes use of the strongest reaction in each material. The setup of the previous experiment was improved on by using high-purity germanium detectors to measure the γ-ray signal with a higher resolution than was previously achieved. A PMMA phantom was also used to simulate the γ-ray background from tissue activation. HTM RV using the data collected in this study yielded range measurements whose average deviation from the expected value was 0.13(22)mm. Significance. Range uncertainty in PT limits the prescribed treatment plan for cancer patients with large safety margins and constrains the direction of the proton beam in relation to any organ at risk. The sub-milimetre range uncertainty achieved in this study using HTM RV, if implemented clinically, would allow for a reduction in the size of safety margins, increasing the therapeutic window for PT.
- 8 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (18) , 185005
Open AccessImproved sub-milimeter range-verification method for proton therapy using a composite hadron tumour marker (HTM)
Objective. The results of a follow-up experiment investigating a novel method for sub-milimetre range verification (RV) in proton therapy (PT) are presented. Approach. The method consists of implanting a hadron tumour marker (HTM) near the planned treatment volume, and measuring the γ-ray signals emitted as a result of activation by the proton beam. These signals are highly correlated with the energy of the beam impinging on the HTM and can provide an absolute measurement of the range of the beam relative to the position of the HTM, which is independent of any uncertainties in beam delivery. Main results. Three candidate HTM materials were identified and combined into a single composite HTM, which makes use of the strongest reaction in each material. The setup of the previous experiment was improved on by using high-purity germanium detectors to measure the γ-ray signal with a higher resolution than was previously achieved. A PMMA phantom was also used to simulate the γ-ray background from tissue activation. HTM RV using the data collected in this study yielded range measurements whose average deviation from the expected value was 0.13(22)mm. Significance. Range uncertainty in PT limits the prescribed treatment plan for cancer patients with large safety margins and constrains the direction of the proton beam in relation to any organ at risk. The sub-milimetre range uncertainty achieved in this study using HTM RV, if implemented clinically, would allow for a reduction in the size of safety margins, increasing the therapeutic window for PT.
- 16 December 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (24) , 245022
Intra- and inter-fraction relative range verification in heavy-ion therapy using filtered interaction vertex imaging
Heavy-ion therapy, particularly using scanned (active) beam delivery, provides a precise and highly conformal dose distribution, with maximum dose deposition for each pencil beam at its endpoint (Bragg peak), and low entrance and exit dose. To take full advantage of this precision, robust range verification methods are required; these methods ensure that the Bragg peak is positioned correctly in the patient and the dose is delivered as prescribed. Relative range verification allows intra-fraction monitoring of Bragg peak spacing to ensure full coverage with each fraction, as well as inter-fraction monitoring to ensure all fractions are delivered consistently. To validate the proposed filtered interaction vertex imaging (IVI) method for relative range verification, a 16 O beam was used to deliver 12 Bragg peak positions in a 40 mm poly-(methyl methacrylate) phantom. Secondary particles produced in the phantom were monitored using position-sensitive silicon detectors. Events recorded on these detectors, along with a measurement of the treatment beam axis, were used to reconstruct the sites of origin of these secondary particles in the phantom. The distal edge of the depth distribution of these reconstructed points was determined with logistic fits, and the translation in depth required to minimize the χ 2 statistic between these fits was used to compute the range shift between any two Bragg peak positions. In all cases, the range shift was determined with sub-millimeter precision, to a standard deviation of the mean of 220(10) μ m. This result validates filtered IVI as a reliable relative range verification method, which should be capable of monitoring each energy step in each fraction of a scanned heavy-ion treatment plan.
- 16 December 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (24) , 245022
Intra- and inter-fraction relative range verification in heavy-ion therapy using filtered interaction vertex imaging
Heavy-ion therapy, particularly using scanned (active) beam delivery, provides a precise and highly conformal dose distribution, with maximum dose deposition for each pencil beam at its endpoint (Bragg peak), and low entrance and exit dose. To take full advantage of this precision, robust range verification methods are required; these methods ensure that the Bragg peak is positioned correctly in the patient and the dose is delivered as prescribed. Relative range verification allows intra-fraction monitoring of Bragg peak spacing to ensure full coverage with each fraction, as well as inter-fraction monitoring to ensure all fractions are delivered consistently. To validate the proposed filtered interaction vertex imaging (IVI) method for relative range verification, a 16 O beam was used to deliver 12 Bragg peak positions in a 40 mm poly-(methyl methacrylate) phantom. Secondary particles produced in the phantom were monitored using position-sensitive silicon detectors. Events recorded on these detectors, along with a measurement of the treatment beam axis, were used to reconstruct the sites of origin of these secondary particles in the phantom. The distal edge of the depth distribution of these reconstructed points was determined with logistic fits, and the translation in depth required to minimize the χ 2 statistic between these fits was used to compute the range shift between any two Bragg peak positions. In all cases, the range shift was determined with sub-millimeter precision, to a standard deviation of the mean of 220(10) μ m. This result validates filtered IVI as a reliable relative range verification method, which should be capable of monitoring each energy step in each fraction of a scanned heavy-ion treatment plan.